Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.
about
A comprehensive review on metabolic syndromeThe safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]Microencapsulated Genetically EngineeredLactobacillus plantarum80 (pCBH1) for Bile Acid Deconjugation and Its Implication in Lowering CholesterolC-reactive protein (CRP)-lowering agentsOptimal lipid modification: the rationale for combination therapyEvaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric studyDo we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?The therapeutic role of niacin in dyslipidemia managementThe metabolic syndromeA "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia.A review on the traditional Chinese medicinal herbs and formulae with hypolipidemic effect.Novel markers of peripheral arterial disease.Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia.Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy.Management of dyslipidemia in women in the post-hormone therapy era.Does nicotinic acid (niacin) lower blood pressure?Niacin extended-release/lovastatin: combination therapy for lipid disorders.Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia.Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.Treating dyslipidemic patients with lipid-modifying and combination therapies.Pharmacotherapy for dyslipidaemia--current therapies and future agents.The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin.Extended-release niacin/lovastatin: the first combination product for dyslipidemia.Pharmacologic treatment of type 2 diabetic dyslipidemia.Complementary therapy to target LDL cholesterol: the role of the ezetimibe/simvastatin combination.Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review.Torcetrapib/atorvastatin combination therapy.Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice.Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS studyNiacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.New evidences for C-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor.Dyslipidaemia in diabetic patients: time for a rethink.Comparative evaluation between chitosan and atorvastatin on serum lipid profile changes in hyperlipidemic cats.Risk factor management to prevent first stroke.Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients.Efficacy and tolerability of adding coenzyme A 400 U/d capsule to stable statin therapy for the treatment of patients with mixed dyslipidemia: an 8-week, multicenter, double-blind, randomized, placebo-controlled study.The mechanism and mitigation of niacin-induced flushing.Niacin's role in the statin era.New evidence for nicotinic acid treatment to reduce atherosclerosis.
P2860
Q21284500-54104063-E102-4F1A-9BA5-4FF18738664CQ24797790-38F3BDCA-4A51-4916-BC63-4C0908CEF45CQ24809565-A508B3C7-DFE7-48A4-AE0A-88C88468E9A1Q28200344-CE68F98A-6334-4642-BA9D-5E0D3B6A5DE8Q28219266-DA3A2F97-501F-4D47-9AC0-D96757964DEEQ28219359-FE902967-297D-49D1-AA2A-7FAC2666AEFAQ28222549-2BBC3552-D6D3-4514-91AC-B057A605AA4CQ28304559-5545E14A-D59A-40C6-B6E0-133E1880FB12Q33569142-89485B7C-5908-424B-801C-9D3E20B10DE6Q33765072-F1F2442A-FE8A-438A-8C9D-6B1F99995F09Q33802196-123CD8FC-BCCE-4DF4-9C86-259B67B2CC43Q33942724-0E5BEC69-555A-4D39-9E46-23F8E679A40CQ33984026-84A956A7-F056-454E-A2CD-089DE30E8832Q34042886-C9B1E85B-694C-4146-A33D-D66F3595FFD4Q34079197-71189EAA-F63C-4D14-ABAE-5B5651554416Q34722828-9AD80E1D-453F-46FA-BDC1-C1DAF988AEBFQ34894236-18688A31-1B09-4CDA-B385-88C062952995Q35020544-822BB76A-AF04-491B-B058-59432BC909C5Q35026444-573349EA-E3EE-4E28-B813-8B285156CC82Q35035100-C9543002-E2E0-4DC7-A099-ADE2F55F7C53Q35125390-27B3AC45-7A02-41BE-A610-4D38D4943DE5Q35574960-4D04296D-4043-48B9-BD70-AA29D090E86FQ35637978-0111F4E9-0E4B-428C-9272-E05990AFA25AQ35821875-83020C5F-DCE2-4862-B413-5FF8BF2CE5A0Q35976827-3BB93775-B971-48FA-8EDB-19140A59F96DQ36012918-3B52BADD-27C2-488C-AC83-D89416D29DD6Q36194119-15FBFBC5-C1A9-4866-9D09-511414AFC4E5Q36265996-128C3DBB-257E-43BA-826C-AD3997CD88DCQ36302760-36FB2BFB-719E-455B-BC81-CA55E0607FE2Q36536280-6AFC7924-96AB-41F8-B121-30AC8C0CC16FQ36540320-FEFABF0F-0FD9-4159-A1BE-9EC2FE98A7FFQ36897456-66990035-5C1D-4E2B-A9DB-132848163AD4Q36909519-6D42A8BB-900C-4AEB-BFC7-EB48822DACBFQ36981142-BABA50A0-AC32-44D9-8B83-7205125C2907Q37153566-074BD59A-FB5D-4CC1-AEF9-E9D127248082Q37310485-FF3492E3-D7B8-48E3-9DC7-6AEC6622EE97Q37436379-268AC8E5-17C2-43EF-B35E-34852762104CQ37582460-D8FD057D-CD41-444C-BA63-81581CE25272Q37766890-6956DFC8-5DE8-431B-BE80-A97ACF0D20D0Q37799365-731950B6-E7C0-4A10-92C4-9DC222DC1421
P2860
Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Long-term safety and efficacy ...... or patients with dyslipidemia.
@en
Long-term safety and efficacy ...... or patients with dyslipidemia.
@nl
type
label
Long-term safety and efficacy ...... or patients with dyslipidemia.
@en
Long-term safety and efficacy ...... or patients with dyslipidemia.
@nl
prefLabel
Long-term safety and efficacy ...... or patients with dyslipidemia.
@en
Long-term safety and efficacy ...... or patients with dyslipidemia.
@nl
P2093
P1476
Long-term safety and efficacy ...... or patients with dyslipidemia.
@en
P2093
Boris Kerzner
Harold E Bays
Kathleen Berra
Laurence K Favrot
Mark E McGovern
Moti L Kashyap
Peter O Kwiterovich
Phillip D Simmons
Phillip D Toth
Stephen D Nash
P304
P356
10.1016/S0002-9149(01)02338-4
P407
P50
P577
2002-03-01T00:00:00Z